A Randomized, Placebo-Controlled, Double-Blind Six Month Study Followed by an Open-Label Extension Phase to Evaluate the Efficacy, Safety and Tolerability of MN-001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Trial Profile

A Randomized, Placebo-Controlled, Double-Blind Six Month Study Followed by an Open-Label Extension Phase to Evaluate the Efficacy, Safety and Tolerability of MN-001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Tipelukast (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Therapeutic Use
  • Sponsors MediciNova
  • Most Recent Events

    • 10 Aug 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 10 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
    • 01 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top